---
title: "T&K released its first-quarter performance, with a net profit attributable to the parent company of 31.546 million yuan, a decrease of 30.62%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237605020.md"
description: "According to the Zhitong Finance APP, T&K released its first-quarter report for 2025, with operating revenue of 185 million yuan, a year-on-year decrease of 2.35%. The net profit attributable to shareholders of the listed company was 31.546 million yuan, a year-on-year decrease of 30.62%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 31.4575 million yuan, a year-on-year decrease of 27.58%. The basic earnings per share were 0.07 yuan"
datetime: "2025-04-25T16:08:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237605020.md)
  - [en](https://longbridge.com/en/news/237605020.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237605020.md)
generator: "portal-rs"
---

# T&K released its first-quarter performance, with a net profit attributable to the parent company of 31.546 million yuan, a decrease of 30.62%

According to the Zhitong Finance APP, T&K (301263.SZ) released its first-quarter report for 2025, showing an operating income of 185 million yuan, a year-on-year decrease of 2.35%. The net profit attributable to shareholders of the listed company was 31.546 million yuan, a year-on-year decrease of 30.62%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 31.4575 million yuan, a year-on-year decrease of 27.58%. The basic earnings per share were 0.07 yuan

### Related Stocks

- [301263.CN](https://longbridge.com/en/quote/301263.CN.md)

## Related News & Research

- [Hyrox founders reclaim majority stake in fitness-racing group with L Catterton-led investors](https://longbridge.com/en/news/298426349.md)
- [Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2](https://longbridge.com/en/news/298452346.md)
- [Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition](https://longbridge.com/en/news/298349678.md)
- [Nootropics Depot Sponsors Future Nutra Innovation Summit](https://longbridge.com/en/news/298602187.md)
- [Resverlogix says new journal studies link apabetalone to lower heart-failure risk](https://longbridge.com/en/news/298584507.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**